1/31/2024 0 Comments Nystatin 5 ml swish and swallow![]() ![]() Other agents that have been investigated with variable responses are oral capsaicin, oral sulfasalazine, and growth factor mouthwashes. Data supporting these management options are limited. Current standard of care focuses on palliation and includes systemic opiate analgesics for moderate to severe mucositis pain, topical anesthetics and mucosal coating agents for moderate pain, and bland rinses for mild pain. ![]() One marketed agent is a recombinant human keratinocyte growth factor, palifermin, and despite its approval to reduce the incidence and duration of oral mucositis, it has seen limited utility due to questionable clinical benefit and high acquisition costs. Unfortunately, few available options have proven useful. Īs a result, many agents and strategies have been investigated to alleviate this pain, to prevent the incidence of mucositis, or to decrease the severity of mucositis. Mucositis also has the potential to impact the effectiveness of cancer treatment as it is a dose-limiting toxicity resulting in cessation or reduction of treatment in 35% of patients receiving chemotherapy. ![]() Pain from oral mucositis has been reported as one of the most debilitating side effect by patients receiving HCT. Mucositis and associated pain are consistently reported as extremely distressing for patients and may involve erythema, inflammation, bleeding, and ulceration. Oral mucositis occurs in approximately 40% of patients receiving standard dose chemotherapy, 80% of patients receiving radiation therapy to the head and neck, and up to 100% of patients undergoing a hematopoietic cell transplant (HCT). Mucositis has significant quality of life and clinical consequences for patients undergoing antineoplastic cytotoxic therapies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |